Expression of Leukotriene C4 Synthase and Plasminogen Activator Inhibitor 1 Gene Promoter Polymorphisms in Sinusitis

2006 ◽  
Vol 20 (5) ◽  
pp. 545-549 ◽  
Author(s):  
Alessandro de Alarcón ◽  
John W. Steinke ◽  
Robert Caughey ◽  
Elizabeth Barekzi ◽  
Kathleen Hise ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Gene Promoter ◽  
Plasminogen Activator Inhibitor ◽  
Leukotriene C4 ◽  
Plasminogen Activator Inhibitor 1 ◽  
Promoter Polymorphisms ◽  
Activator Inhibitor ◽  
Leukotriene C4 Synthase

Plasminogen activator inhibitor-1 and outcome after femoropopliteal angioplasty: analysis of genotype and plasma levels

2003 ◽  
Vol 90 (10) ◽  
pp. 717-723 ◽  
Author(s):  
Martin Schillinger ◽  
Markus Exner ◽  
Schila Sabeti ◽  
Christine Mannhalter ◽  
Erich Minar ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Plasma Levels ◽  
Gene Promoter ◽  
Plasminogen Activator Inhibitor ◽  
Cox Proportional Hazards ◽  
Nucleotide Position ◽  
Plasminogen Activator Inhibitor 1 ◽  
Late Restenosis ◽  
Activator Inhibitor ◽  
Pai 1

SummaryPlasminogen activator inhibitor-1 (PAI-1) is suggested to be involved in the pathophysiology of early thrombosis and late restenosis after percutaneous transluminal angioplasty (PTA). The role of the PAI-1 promoter genotype in this context is indeterminate. We investigated the association of the (4G/5G) polymorphism at nucleotide position (–675) in the PAI-1 gene promoter, PAI-1 plasma levels, and postangioplasty outcome after femoropopliteal PTA.We studied 251 consecutive patients who underwent femoropopliteal PTA. In a subgroup of 86 patients PAI-1 plasma levels at baseline,8,24 and 48 hours postintervention were measured and correlated to the genotype. Patients were followed for early thrombosis and the late restenosis (≥50%) within 12 months. Multivariate Cox proportional hazards analysis was performed to assess the association between the PAI-1 genotype and PTA failure.Results show that the PAI-1 genotype was neither associated with PAI-1 plasma levels (p=0.40) nor the change of PAI-1 from baseline to 8 (p=0.39), 24 (p=0.86) and 48 hours (p=0.89). Three out of 35 homozygous (4G/4G) patients (9%) had early thrombotic reocclusions, compared to two out of 153 heterozygous (4G/5G) patients (1%) and none of the 63 homozygous (5G/5G) patients (p=0.007). Restenosis after median 5 months (interquartile range 3 to 9) was found in 117 patients (42%), without significant association between the PAI-1 genotype and late postangioplasty failure (Log Rank p=0.95).We can conclude that carriers of the 4G allele exhibited a higher frequency of early thrombotic reocclusions after percutaneous angioplasty. However, the PAI-1 gene promoter polymorphism (4G/5G) was not associated with PAI-1 plasma levels or late postangioplasty restenosis.

scholarly journals Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism – a meta-analysis and systematic review

VASA ◽  
2020 ◽  
Vol 49 (2) ◽  
pp. 141-146 ◽  
Author(s):  
Qiang Zhang ◽  
YunRui Jin ◽  
XueMei Li ◽  
XingQiao Peng ◽  
Na Peng ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Plasminogen Activator ◽  
Meta Analysis ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Promoter Polymorphisms ◽  
Potential Biomarker ◽  
Activator Inhibitor Type ◽  
Activator Inhibitor ◽  
Pai 1

Summary: Background: A 4G/5G polymorphism in the promoter region of the plasminogen activator inhibitor type 1 (PAI-1) gene has been reported to enhance the plasma levels of PAI-1, which plays an important role in fibrinolysis disorders and venous thromboembolism, but a large number of studies have reported inconclusive results. Therefore, we performed a meta-analysis to analysis these associations. Materials and methods: We performed a publication search for articles published before April 2019 by using the electronic databases of web of Science, Embase, PubMed, CNKI, CBM and WanFang data with the following terms “PAI-1”, “polymorphism”, “Venous Thromboembolism”. Two investigators independently extracted data and assessed study quality. Statistical analyses were undertaken using Stata 14.0. Results: A total of 27 studies, with 3135 patients and 5346 controls were included. Overall, the variant PAI-1 4G/4G and PAI-1 4G/5G was associated with venous thromboembolism risk, compared with the PAI-1 5G/5G allele in the populations included in the analysis. Stratified analysis revealed that PAI-1 4G/4G and PAI-1 4G/5G genotypes were associated with an increased VTE risk among Asia populations in all five genetic models. Conclusions: The PAI-1 4G/5G polymorphism may be a potential biomarker of VTE risk, particularly in Asia populations. Further larger studies with multi-ethnic populations are required to further assess the association between PAI-1 4G/4G polymorphisms and VTE risk.

Sign in / Sign up

Export Citation Format

Share Document